p450 - publications

Predict more p450 - ligand interactions now!


1. J Alzheimers Dis. 2012 Mar 30. [Epub ahead of print]

Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on
Donepezil Efficacy in Alzheimer's Disease Patients.

Albani D, Boneschi FM, Biella G, Giacalone G, Lupoli S, Clerici F, Benussi L,
Ghidoni R, Galimberti D, Squitti R, Mariani S, Confaloni A, Bruno G, Mariani C,
Scarpini E, Binetti G, Magnani G, Franceschi M, Forloni G.

Department of Neuroscience, "Mario Negri" Institute for Pharmacological Research,
Milan, Italy.

Alzheimer's disease (AD) is a neurodegenerative disorder often treated with
donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable,
probably based on patients' genetic background in donepezil metabolizing enzymes,
including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical
response to donepezil and a common variant (rs1080985) of CYP2D6, previously
reported to be associated with poor response to the drug. In a sample of 415 AD
cases, we found evidence of association between rs1080985 and response to
donepezil after 6 months of therapy (OR [95% CI]: 1.74 [1.01-3.00], p = 0.04).
Rs1080985 might be useful as predictor of poor response to short-term donepezil
treatment.

PMID: 22465999 [PubMed - as supplied by publisher]